Venue: Le Royal Meridien Shanghai (上海世贸皇家艾美酒店), Shanghai, China
789 Nanjing Road East, Shanghai 200001, China
Tel: +86 21 3318 9999
Brochure: 
PCAF 2013 Brochure with Registration Form.pdfFees: CNY 5,500 for Pharma China subscribers and employees of RDPAC member companies. CNY 6,300 for others
Contact: David Xue or Jenny Wang
Event Highlights
- Contemporary trends & issues in Chinese Pharma in 2012 and early 2013
- Healthcare reform and policy impacts on the Chinese pharma sector
- Pharma-related regulatory developments and market access issues
- Changing dynamics in Chinese pharma/healthcare landscape
- Pharmaceutical/healthcare market outlook for 2013 and beyond
- Interactive discussion and brainstorming with our panel of top experts
Introduction
The Chinese pharmaceutical industry and market in 2012 was characterized by slowing growth, falling profitability, mixed regulatory developments setting higher industry standards to improve drug safety and boosting drug review efficiency, renewed price cutting initiatives disregarding higher costs and expenditures of the industry, superficial healthcare reform progress driven primarily by cost containment measures, fallen healthcare quality & growing drug safety incidents, worsening patient physician relations, and non-stop repositioning of the pharma industry adapting to new realities.
As predicted, China's ongoing healthcare reform last year was limited by structural flaws, lack of central government will to finance reform, failures to coordinate agendas of different agencies and balance conflicting interest of stakeholders, fiscal challenges of local governments, and belated reform of the medical service industry.
The Chinese government did step up their healthcare investment somewhat, but it is far from enough to finance the reform goals, and the reform last year had to be driven primarily by comprehensive cost cutting initiatives.
Besides, Central government agencies including SFDA, MOH and NDRC have been leading the efforts of strengthening drug regulation with emphasis on price control, drug safety, 2010 GMP, drug registration system reform and OTC drug management, while other agencies such as MOFCOM and the MIIT have stepped up their industrial management role of the pharmaceutical industry.
Faced with unprecedented challenges, large pharmaceutical companies, represented by state-controlled companies and MNCs, continued to reposition themselves through M&As, diversification drives, alliances and partnerships, and capacity building for both manufacturing and R&D.
In fact, the pharmaceutical industry in China continued to outperform other industries last year in spite of a fresh array of policy turbulences, slowing economy and a host of other challenges, and it managed to grow at around 20%.
MOH stated recently that the healthcare reform has reached a stage of "deep water" and "tough battle" and the government must emphasize its efforts on major issues including primary healthcare, basic medical insurance and essential drugs in 2013.
There is no doubt the healthcare reform will go on with unchanged slogans. In reality, both central and local governments will be more financially strapped this year to achieve original reform objectives and they will be forced to rely on cost containment even more. The aftermath will be fallen quality of healthcare, increased safety incidents and reduced overall healthcare efficiency, potentially leading to social unrests in a period of political sensitivity.
Given the present market environment, it is anticipated that pharma industry and market growth in the near future would no longer match the high rates seen in 2010 and 2011.
But don't be discouraged prematurely. The upcoming Year of Snake in 2013 is also meant for steady progress and achievement for those with creativity, focus and discipline. Only those with flexibility and creative strategies will succeed in this increasingly complex and challenging market.
The Pharma China Annual Forum 2013 is an English language annual pharma industry event oriented for foreign drug companies in China. The event's emphasis is on healthcare policies, drug regulations, market access issues as well as potential impacts of upcoming changes on the Chinese pharma industry. In addition, various trends in M&A, R&D and licensing, healthcare landscape, as well as future outlook will be explored and discussed.
At least 11 leading experts, together with their guests and partners, will share their knowledge, insights and expertise in contemporary market trends, healthcare reform and policy direction, drug regulation and creative strategies. The presentation will be followed by an interactive panel discussion with speakers and other experts.
Fee (covering attendance, lunch and refreshments)
CNY 5,500 – Pharma China subscribers and employees of RDPAC member companies
CNY 6,300 – All other non-subscribers of Pharma China
Sponsorship opportunities
Please contact us about sponsorship packages for refreshments and after-event cocktail. For more details, please download information in PDF:
Sponsorship Packages for Pharma China Annual Forum 2013.pdf
Registration
Spaces are limited to 80 participants and priority is given to
Pharma China subscribers. Please contact:
David Xue
Tel: +86 10 8530-0937 Cell: +86 18601267831